Track the innovations and Trends shaping the future of health, wellness and fitness
Powered by our proprietary AI Foresight Intelligence System, we track emerging innovations and trends, score their future market impact, and identify innovations that signal the potential to elevate health, wellness, and fitness markets.
Join Business leaders, Founders, Investors, Innovators, Marketers and Practitioners
Innovations and trends in health, wellness, and fitness are evolving faster than ever.
Most businesses see and act on trends too late. Every week, 1000’s of signals provide new technologies, products, consumer behaviours, and scientific breakthroughs reshaping health, wellness and fitness faster than ever.
But more information hasn’t made decision-making easier. It’s made it harder.
- What is real vs. hype?
- Which innovations will actually scale?
- How fast will markets shift?
- Where should you act now?
Most platforms give you information.
Few give you clarity.
The future is often buried in noise. Our Foresight System filters the noise into structured intelligence.
Elevate Ninety transforms fragmented signals into structured foresight.
We don’t just surface what innovations and trends are emerging, we quantify its potential, track its trajectory and connect it to real-world decisions through our Foresight Index.
So instead of reacting to change, you can anticipate it and act early before change becomes mainstream.
AI Powered System Built for Decision Making
Elevate Ninety is built on a dual intelligence model:
AI-powered detection + human foresight analysis. We turn raw signals and information into decision making intelligence.
A foresight intelligence system built for decision makers and innovators in health, wellness and fitness.
1. AI Signal Detection
We continuously scan thousands of signals across scientific research, clinical validation, product launches, patents, funding, mergers & acquisitions, behavioural shifts.
2. Structured Scoring
We convert signals into structured scoring for each innovation within the Foresight Index, a curated ranking system measuring future impact potential and market maturity.
3. Continuous Tracking
Combing AI and human analysis, we monitor how innovations and trends evolve, identifying acceleration, inflection points, market shifts and forces driving new innovation.
4. Decision Making Tools
We provide tools such as dashboards, real-time content, reports and AI assistants to ensure users have strategic answers at their finger tips to act early on forces shaping the future.
The Pulse Delivers Signals and Foresight Every Week
Sign up to our newsletter, The Pulse to receive weekly foresight and signals that give you clearer understanding of the future in health, wellness and fitness
Latest Signals
Vicore and Alex reported positive pilot results for a CBT-based digital therapeutic designed to support anxiety in idiopathic pulmonary fibrosis patients. The signal points toward digital therapeutics moving beyond broad wellness use cases into disease-linked mental health support, where clinical need, pathway clarity and measurable outcomes are easier to define.
Lilly has reported Phase 3 data for Foundayo, its oral GLP-1 candidate orforglipron, ahead of the ADA Scientific Sessions, positioning it as an oral incretin therapy without food or water restrictions. The signal points toward a more scalable, choice-led phase of obesity and diabetes treatment, where delivery format becomes a major adoption driver.
Lucis has raised $20m to scale its AI-powered preventive health platform across Europe, combining 110-plus blood biomarkers with personalised guidance, while Cardio Diagnostics is positioning precision cardiovascular testing in the employer benefits market. Together, the signal suggests blood biomarkers are being repackaged from clinical diagnostics into AI-led prevention, consumer engagement and population-risk management.
PolyBio has launched the VIPER programme to validate biomarkers for Long COVID, aiming to establish objective biological measures for diagnosis and research. The initiative signals growing efforts to move Long COVID from a symptom-defined condition toward a biomarker-supported clinical category.